Oppenheimer Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.4M | Sell |
307,218
-5,220
| -2% | -$137K | 0.08% | 287 |
|
|
2026
Q1 | $8.77M | Buy |
312,438
+143,664
| +85% | +$3.82M | 0.1% | 228 |
|
|
2025
Q4 | $4.2M | Sell |
168,774
-30,860
| -15% | -$778K | 0.05% | 335 |
|
|
2025
Q3 | $5.09M | Sell |
199,634
-120,272
| -38% | -$2.97M | 0.06% | 337 |
|
|
2025
Q2 | $7.75M | Sell |
319,906
-3,565
| -1% | -$83.1K | 0.09% | 250 |
|
|
2025
Q1 | $8.2M | Buy |
323,471
+32,203
| +11% | +$843K | 0.1% | 226 |
|
|
2024
Q4 | $7.73M | Sell |
291,268
-36,742
| -11% | -$997K | 0.09% | 234 |
|
|
2024
Q3 | $9.49M | Sell |
328,010
-160
| -0% | -$4.67K | 0.11% | 204 |
|
|
2024
Q2 | $9.18M | Buy |
328,170
+27,178
| +9% | +$748K | 0.12% | 204 |
|
|
2024
Q1 | $8.35M | Sell |
300,992
-11,660
| -4% | -$324K | 0.12% | 195 |
|
|
2023
Q4 | $9M | Sell |
312,652
-46,306
| -13% | -$1.4M | 0.13% | 196 |
|
|
2023
Q3 | $11.9M | Sell |
358,958
-12,387
| -3% | -$438K | 0.18% | 132 |
|
|
2023
Q2 | $13.6M | Sell |
371,345
-6,576
| -2% | -$256K | 0.2% | 125 |
|
|
2023
Q1 | $15.4M | Buy |
377,921
+575
| +0.2% | +$24.8K | 0.24% | 96 |
|
|
2022
Q4 | $19.3M | Sell |
377,346
-2,902
| -0.8% | -$139K | 0.31% | 73 |
|
|
2022
Q3 | $16.6M | Buy |
380,248
+37,984
| +11% | +$1.85M | 0.29% | 78 |
|
|
2022
Q2 | $17.9M | Sell |
342,264
-2,633
| -0.8% | -$134K | 0.3% | 74 |
|
|
2022
Q1 | $17.9M | Sell |
344,897
-771
| -0.2% | -$40K | 0.25% | 93 |
|
|
2021
Q4 | $20.4M | Sell |
345,668
-67,798
| -16% | -$3.36M | 0.27% | 91 |
|
|
2021
Q3 | $17.8M | Sell |
413,466
-6,587
| -2% | -$292K | 0.25% | 89 |
|
|
2021
Q2 | $16.4M | Buy |
420,053
+15,442
| +4% | +$601K | 0.23% | 100 |
|
|
2021
Q1 | $14.7M | Buy |
404,611
+4,731
| +1% | +$168K | 0.23% | 105 |
|
|
2020
Q4 | $14.7M | Sell |
399,880
-333
| -0.1% | -$12.2K | 0.25% | 94 |
|
|
2020
Q3 | $13.9M | Sell |
400,213
-96,393
| -19% | -$3.38M | 0.27% | 88 |
|
|
2020
Q2 | $15.4M | Sell |
496,606
-45,785
| -8% | -$1.56M | 0.32% | 74 |
|
|
2020
Q1 | $16.8M | Buy |
542,391
+52,022
| +11% | +$1.77M | 0.41% | 51 |
|
|
2019
Q4 | $18.2M | Buy |
490,369
+41,251
| +9% | +$1.47M | 0.39% | 48 |
|
|
2019
Q3 | $15.3M | Buy |
449,118
+2,207
| +0.5% | +$80.3K | 0.34% | 63 |
|
|
2019
Q2 | $18.4M | Sell |
446,911
-8,187
| -2% | -$325K | 0.41% | 45 |
|
|
2019
Q1 | $18.3M | Buy |
455,098
+839
| +0.2% | +$33.6K | 0.41% | 44 |
|
|
2018
Q4 | $18.8M | Buy |
454,259
+4,651
| +1% | +$193K | 0.47% | 42 |
|
|
2018
Q3 | $18.8M | Sell |
449,608
-6,772
| -1% | -$261K | 0.42% | 48 |
|
|
2018
Q2 | $15.7M | Sell |
456,380
-273,709
| -37% | -$9.35M | 0.38% | 62 |
|
|
2018
Q1 | $24.6M | Sell |
730,089
-5,791
| -0.8% | -$199K | 0.62% | 24 |
|
|
2017
Q4 | $24.9M | Hold |
735,880
| – | – | 0.66% | 24 |
|
|
2017
Q3 | $24.9M | Buy |
735,880
+72,939
| +11% | +$2.34M | 0.65% | 25 |
|
|
2017
Q2 | $21.1M | Sell |
662,941
-2,661
| -0.4% | -$83.9K | 0.58% | 29 |
|
|
2017
Q1 | $21.6M | Buy |
+665,602
| New | +$21M | 0.62% | 25 |
|
Other funds holding PFE
Oppenheimer Asset Management's PFE Position: Q2 2026 in Review
Oppenheimer Asset Management reduced its Pfizer (PFE) stake by 1.7% in Q2 2026, selling an estimated $137K and leaving 307,218 shares worth $7.4M. The position accounts for 0.08% of the portfolio, ranked #287.
Oppenheimer Asset Management first reported a position in PFE in Q1 2017 and has held it in 38 quarters since. The position peaked at $24.9M in Q4 2017. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Oppenheimer Asset Management held 307,218 shares of Pfizer worth $7.4M as of Q2 2026.
- Oppenheimer Asset Management sold 5,220 Pfizer shares in Q2 2026, an estimated $137K.
- Pfizer made up 0.08% of Oppenheimer Asset Management's portfolio in Q2 2026, its #287 holding.
- Oppenheimer Asset Management first reported a position in Pfizer in Q1 2017 and has held it in 38 quarters since.
- Oppenheimer Asset Management's Pfizer position peaked at $24.9M in Q4 2017.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.